11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $296M | $24M | 0.0% | 33.3% | $127M | — | $215M |
| 2024 | $351M | $880000 | 0.0% | 26.5% | $103M | $199M | $89M |
| 2023 | $443M | -$1.0B | 0.0% | -213.5% | $183M | $398M | $92M |
| 2022 | $411M | $175M | 0.0% | 61.0% | $274M | $396M | $656M |
| 2021 | $414M | $528M | 0.0% | 56.1% | $262M | $454M | $620M |
| 2020 | $390M | $106M | 99.2% | 36.7% | $167M | $430M | $363M |
| 2019 | $428M | $22M | 94.4% | 28.0% | $4M | — | $177M |
| 2018 | $347M | -$282M | 90.6% | -43.5% | -$71M | — | $173M |
| 2017 | $298M | -$117M | 93.6% | -5.2% | -$104M | — | $126M |
| 2016 | $274M | -$82M | 99.3% | -18.9% | -$30M | — | $54M |
| 2015 | — | -$143M | — | — | -$111M | $221M | $261M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $107M | $41M | 0.0% | 68.1% | — | — | $220M |
| Dec '25 | $48M | -$2M | 0.0% | 14.3% | $75M | — | $215M |
| Sep '25 | $122M | $40M | 0.0% | 61.8% | $48M | $200M | $140M |
| Jun '25 | $85M | $24M | 0.0% | 53.2% | -$15M | $199M | $93M |
| Mar '25 | $41M | -$37M | 0.0% | -70.7% | $20M | $199M | $108M |
| Dec '24 | $91M | $2M | 0.0% | 34.8% | $15M | $199M | $89M |
| Sep '24 | $92M | $4M | 0.0% | 28.0% | $10M | $199M | $88M |
| Jun '24 | $94M | -$860000 | 0.0% | 26.5% | $33M | $199M | $106M |
| Mar '24 | $75M | -$4M | 0.0% | 14.7% | $45M | $398M | $122M |
| Dec '23 | $118M | -$1M | 0.0% | 32.0% | $36M | $398M | $92M |
| Sep '23 | $114M | $15M | 0.0% | 35.2% | $32M | $397M | $110M |
| Jun '23 | $107M | -$1.1B | 0.0% | -1008.7% | $35M | $397M | $175M |
| Mar '23 | $104M | $46M | 0.0% | 57.8% | $80M | $397M | $740M |
| Dec '22 | $107M | $49M | 0.0% | 63.8% | $79M | $396M | $656M |
| Sep '22 | $109M | $50M | 0.0% | 63.0% | $69M | $396M | $574M |
| Jun '22 | $97M | $37M | 0.0% | 57.2% | $61M | $395M | $504M |
| Mar '22 | $98M | $39M | 0.0% | 59.3% | $64M | $516M | $593M |
| Dec '21 | $117M | $41M | 0.0% | 48.3% | $64M | $454M | $620M |
| Sep '21 | $104M | $56M | 0.0% | 62.8% | — | $448M | $574M |
| Jun '21 | $104M | $391M | 0.0% | 62.6% | — | $442M | $493M |
How the market has priced IRWD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Ironwood Pharmaceuticals Inc's revenue has declined 5.3% per year, and net income declined 25.7% per year. These are computed facts, not advice.
As of FY2025, Ironwood Pharmaceuticals Inc reported — of total debt against $215M of cash; operating income covered interest expense 3.0×.
In FY2025, gross margin was —, operating margin 33.3%, and net margin 8.1%.
As of Jun '26, Ironwood Pharmaceuticals Inc traded at a price-to-earnings ratio of about 26.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.